Results 111 to 120 of about 22,692,331 (249)

Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.

Circulation Research, 2016
Vaibhav B. Patel, J. Zhong, M. Grant, G. Oudit   +3 more
semanticscholar   +1 more source

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, EarlyView.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy

European Journal of Clinical Investigation, EarlyView.
Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda, Amedeo Tirandi, Giulio Leo, Davide Di Vece, Gemma Vilahur, Aldo Bonaventura, Elena Osto, Stefano Ministrini, Simon Kraler, Petra Kleinbogard, Giovanni Camici, Federico Carbone, Fabrizio Montecucco, Luca Liberale   +13 more
wiley   +1 more source

Characteristics, therapeutic pathway and the economic burden of patients with drug‐resistant epilepsy: A real‐world analysis following the introduction of cenobamate in Italy

Epilepsia, EarlyView.
Abstract Objectives Drug‐resistant epilepsy (DRE) remains a major clinical challenge, affecting approximately one‐third of patients with epilepsy. Cenobamate, a novel antiseizure medication (ASM) approved in Italy in 2022, has shown promise in clinical trials. However, real‐world data on its use, especially economic evaluations, remain limited.
Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Margherita Andretta, Marcello Bacca, Antonietta Barbieri, Fausto Bartolini, Alessandro Brega, Maria Rosaria Cillo, Francesco Colasuonno, Stefania Dell'Orco, Fulvio Ferrante, Stefano Grego, Antonella Lavalle, Daniela Mancini, Maurizio Pastorello, Romina Pagliaro, Cataldo Procacci, Camilla Scandolara, Patrizia Schiavone, Loredana Ubertazzo, Paola Valpondi, Adriano Vercellone, Alberto Zucchi, Maria Ciappetta, Domenico Lucatelli, Andrea Cinti Luciani, Luca Degli Esposti   +27 more
wiley   +1 more source

Renal renin-angiotensin system —What supports and breaks the circle of life—

, 2014
Shoji Kagami
openalex   +2 more sources

Sex differences in cardiovascular actions of the renin–angiotensin system

Clinical Autonomic Research, 2020
D. Medina, Darren Mehay, Amy C. Arnold
semanticscholar   +1 more source

Molecular basis of domain‐specific angiotensin I‐converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat

The FEBS Journal, EarlyView.
Inhibition of angiotensin I‐converting enzyme is an effective strategy for the treatment of hypertension. However, the clinically available ACE inhibitors cause side effects due to nonselective inhibition of the two catalytic domains of ACE (nACE and cACE).
Kyle S. Gregory, Vinasha Ramasamy, Edward D. Sturrock, K. Ravi Acharya   +3 more
wiley   +1 more source

Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale

Geriatrics &Gerontology International, EarlyView.
ABSTRACT The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy.
Masaki Mogi, Shuang Liu, Yasuyuki Suzuki, Yuuka Shibata, Shizuo Yamada   +4 more
wiley   +1 more source

Screening and Diagnosis of Primary Aldosteronism in Patients Using Renin-Angiotensin System Inhibitors. [PDF]

J Clin Hypertens (Greenwich)
Wang Q, Dong H, Li HW, Zou YB, Jiang XJ.
europepmc   +1 more source

Effects of chronic administration of spirapril, a new angiotensin converting enzyme inhibitor, on blood pressure and renin-angiotensin system in normotensive rats

, 1990
Hamao Toda, Hisayo Oohata, Takeshi Suzuki, Kazuko Fujimoto, Koichiro Kawashima   +4 more
openalex   +1 more source